Blood sampling method for sleep studies v2

  • Research type

    Research Study

  • Full title

    Validation of blood sampling method for sleep studies (15-021)

  • IRAS ID

    213444

  • Contact name

    Frans van den Berg

  • Contact email

    rec@hmrlondon.com

  • Sponsor organisation

    Hammersmith Medicines Research

  • Eudract number

    2000-123456-78

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Hammersmith Medicines Research (HMR) occasionally does studies of medicines that might affect people’s sleep. During such studies, we might want to take blood samples from participants during the night, without disturbing their sleep or waking them up. So we’re trying different ways of taking blood samples, to see what method would work best during a sleep study. We plan to do several ‘projects’ during this study; we’ll test a different method in each project. For each method, we'll take blood samples using a cannula (small plastic tube inserted into a vein in the arm) attached to a long thin tube. We'll give an infusion (slow injection) of saline (salt water) through the tube and cannula to stop blood clotting in the equipment.

    This is not a study of a medicine. But in some of the projects, we might give volunteers a low dose of a medicine called heparin, by slow injection into a vein, as part of the blood sampling method.

    In each project, there’ll be up to 60 healthy participants, aged 18–80 years. Participants should finish the study within a few weeks, but, depending on the project, it could take up to 4 months. They’ll attend HMR for up to 5 visits: 1 screening visit, and up to 4 study sessions, during which we’ll test a blood collection method. Depending on the project, one or more study sessions might require an overnight stay on the ward.

    The study will take place at 1 centre in London: HMR.

  • REC name

    West Midlands - Black Country Research Ethics Committee

  • REC reference

    16/WM/0375

  • Date of REC Opinion

    5 Oct 2016

  • REC opinion

    Further Information Favourable Opinion